Who is sponsoring NCT04537065?

NCT04537065 is sponsored by Ameera Gamal Abdelhameed.

What drugs are being tested in NCT04537065?

Interventions in NCT04537065: cycloplegic refraction.

What condition does NCT04537065 study?

NCT04537065 studies Retinopathy of Prematurity.

Is NCT04537065 still recruiting?

NCT04537065 is currently completed. Last updated 3 September 2020.

Last reviewed 2020-09-03 · How we verify

NCT04537065

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long Term Outcome of Intravitreal Ranibizumab for ROP

Completed Last updated 3 September 2020

What this trial tests

trial testing cycloplegic refraction in Retinopathy of Prematurity in 140 participants. Completed in 1 September 2018.

Timeline

1 April 2018

Primary endpoint
1 September 2018

1 September 2018

Quick facts

Lead sponsor	Ameera Gamal Abdelhameed
Status	Completed
Study type	OBSERVATIONAL
Enrollment	140
Start date	1 April 2018
Primary completion	1 September 2018
Estimated completion	1 September 2018
Sites	1 location across Egypt

Drugs / interventions tested

cycloplegic refraction

Conditions studied

Retinopathy of Prematurity — all drugs for Retinopathy of Prematurity →

Sponsor

Ameera Gamal Abdelhameed — full company profile →

Who can join

Eligibility, any sex, with Retinopathy of Prematurity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

premature infants who had a history of intravitreal injection of (Ranibizumab) not less than one year were examined for refractive state and biometry

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Retinopathy of Prematurity

Currently open trials in the same condition.

NCT05558059 — Imaging Retinal Vasculature in Infant Eyes · recruiting
NCT06672913 — Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study · NA · recruiting
NCT06109285 — Validation of i-ROP DL to Detect More Than Mild ROP · NA · active not recruiting
NCT06315556 — An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Pret · recruiting
NCT06265363 — Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW >1500 Grs or GA ≥33 Wks in Turkey. · recruiting

Other Ameera Gamal Abdelhameed trials

Trials by the same sponsor.

NCT04539106 — Intravitreal Ranibizumab in Recurrent ROP · completed
NCT04430647 — Phaco-UCP Versus Phaco Alone for OAG and Cataract · NA · completed
NCT04433936 — Corneal Tomographic Parameters in TGD · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04537065 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ameera Gamal Abdelhameed
Last refreshed: 3 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04537065.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing